Population pharmacokinetic characteristics of sirolimus in healthy Chinese subjects and renal transplant patients

被引:4
|
作者
Wang, Miao [1 ,2 ]
Duan, Bao-ling [2 ]
Yuan, Yin-jin [3 ]
Su, Xia [1 ]
Zheng, Hang [1 ]
Wang, Fu-sheng [2 ]
Sun, He [1 ]
机构
[1] Tianjin Univ, Sch Pharmaceut Sci & Technol, 92 Weijin Rd, Tianjin 300072, Peoples R China
[2] North China Pharmaceut Grp Corp, New Drug Res & Dev Ctr, Natl Engn Res Ctr Microbial Med, Shijiazhuang, Hebei, Peoples R China
[3] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China
关键词
renal transplant patients; healthy subjects; population pharmacokinetics; sirolimus; cyclosporine; CLINICAL PHARMACOKINETICS; PEDIATRIC-PATIENTS; RAPAMYCIN; SAFETY; CYCLOSPORINE; VOLUNTEERS; RECIPIENTS; REJECTION; EFFICACY; ADULT;
D O I
10.5414/CP202499
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: To identify the factors affecting the pharmacokinetics (PKs) of sirolimus in healthy Chinese subjects and renal transplant patients. Methods: A population PK model of sirolimus was constructed using dense data from 22 healthy volunteers and sparse data from 105 renal transplant patients. Results: The data were well described by a two-compaitment model with first-order absorption. The estimates of absorption rate constant (Ka), clearance (CL/F), and central volume of distribution (V2/F) were 0.24 h(-1), 8.81 L/h, and 676 L, respectively. The CL/F in renal transplant patients was 45.5% lower than that in healthy subjects. Based on the final model, CL/F decreased significantly with increasing cyclosporine (CsA) daily dose and age. A decrease of 7.3% in CL/F for every 100-mg increase in the CsA daily dose and a decrease of 34.2% in CL/F for every 20-year increase in age was observed. Moreover, V2/F increased significantly with increasing serum creatinine in our study. However, the range of serum creatinine concentration and the interindividual variability for V2/F are large. Conclusion: This is the first study to characterize the population PKs of sirolimus using a two-compartment model in healthy Chinese subjects and renal transplant patients. A decrease of 7.3% in the sirolimus CL/F for every 100-mg increase in the CsA daily dose and a decrease of 34.2% in the sirolimus CL/F for every 20-year increase in age was observed, which allowed us to better optimize sirolimus dosing regimens in Chinese renal transplant patients.
引用
收藏
页码:433 / 441
页数:9
相关论文
共 50 条
  • [21] PHARMACOKINETIC STUDY OF RASAGILINE IN HEALTHY CHINESE SUBJECTS
    Deng, Pan
    Zhong, Dafang
    Duan, Xiaotao
    Ma, Jinfei
    Chen, Xiaoyan
    DRUG METABOLISM REVIEWS, 2008, 40 : 169 - 169
  • [22] Pharmacokinetic study of saxagliptin in healthy chinese subjects
    Li H.
    Yang L.
    Tou C.K.P.
    Patel C.G.
    Zhao J.
    Clinical Drug Investigation, 2012, 32 (7) : 465 - 473
  • [23] POPULATION PHARMACOKINETIC ANALYSIS OF RILZABRUTINIB IN HEALTHY SUBJECTS AND PATIENTS WITH PEMPHIGUS.
    Ge, S.
    Li, M.
    Lu, Q.
    Katragadda, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S96 - S96
  • [24] Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine
    Fiedler-Kelly, Jill B.
    Cohen-Barak, Orit
    Morris, Denise N.
    Ludwig, Elizabeth
    Rasamoelisolo, Michele
    Shen, Honglue
    Levi, Micha
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (12) : 2721 - 2733
  • [25] POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF EPTIFIBATIDE IN THE INHIBITION OF PLATELET AGGREGATION IN HEALTHY CHINESE SUBJECTS
    Li, Qinmei
    Zhang, Hong
    Wu, Min
    Liu, Jingrui
    Li, Cuiyun
    Ding, Yanhua
    DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : S83 - S84
  • [26] Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Lefamulin in Healthy Chinese Subjects
    Hu, Yingying
    Wei, Qiong
    Bian, Xingchen
    Yang, Xinyi
    Yu, Jicheng
    Wang, Jingjing
    Yang, Haijing
    Cao, Guoying
    Wu, Xiaojie
    Zhang, Jing
    ANTIBIOTICS-BASEL, 2023, 12 (09):
  • [27] Pharmacodynamic monitoring of cyclosporine in healthy subjects and renal transplant patients.
    Kuzuya, Takafomi
    Kobayashi, Takaaki
    Nagasaka, Takaharu
    Miwa, Yoko
    Katayama, Akio
    Uchida, Kazuharu
    Nakao, Akimasa
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 336 - 336
  • [28] CONVERSION TO SIROLIMUS IN PEDIATRIC RENAL TRANSPLANT POPULATION.
    Azocar, M.
    Delucchi, A.
    Lillo, A.
    Guerrero, J.
    Cano, F.
    PEDIATRIC NEPHROLOGY, 2009, 24 (09) : 1877 - 1877
  • [29] Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients.
    Morelon, E
    Stern, M
    Israël-Biet, D
    Corréas, JM
    Danel, C
    Mamzer-Bruneel, MF
    Peraldi, MN
    Kreis, H
    TRANSPLANTATION, 2001, 72 (05) : 787 - 790
  • [30] Population Pharmacokinetic Analysis of Istradefylline in Healthy Subjects and in Patients With Parkinson's Disease
    Knebel, William
    Rao, Niranjan
    Uchimura, Tatsuo
    Mori, Akihisa
    Fisher, Jeannine
    Gastonguay, Marc R.
    Chaikin, Philip
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (01): : 40 - 52